Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
{{output}}
Background: The proteasome inhibitor bortezomib (BTZ) is successfully applied in the treatment of multiple myeloma, but its efficacy is restricted by the wide-spread occurrence of resistance. Metabolic alterations play an importa... ...
